Liver Cancer Diagnostics Market Share Report, 2023 – 2032

Liver Cancer Diagnostics Market - By Test Type (Laboratory Test, Imaging Test, Biopsy, Endoscopy, Genomic Test), By End-use (Hospitals, Diagnostic Laboratories, Academic and Research Institutes), & Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Industry coverage

1.2&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.6&nbsp;&nbsp;&nbsp; Data validation

1.7&nbsp;&nbsp;&nbsp; Data Sources

1.7.1&nbsp;&nbsp;&nbsp; Primary

1.7.2&nbsp;&nbsp;&nbsp; Secondary

1.7.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.7.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Liver cancer diagnostics industry 360&ordm; synopsis, 2018 &ndash; 2032

2.2&nbsp;&nbsp;&nbsp; Business trends

2.3&nbsp;&nbsp;&nbsp; Regional trends

2.4&nbsp;&nbsp;&nbsp; Test Type trends

2.5&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Liver Cancer Diagnostics Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of liver cancer

3.2.1.2&nbsp;&nbsp;&nbsp;Technological advancements in liver cancer diagnostics

3.2.1.3&nbsp;&nbsp;&nbsp;Rising awareness and screening programs targeting high-risk populations

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of diagnostic tests

3.2.2.2&nbsp;&nbsp;&nbsp;Risk of inaccurate of false results

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By test type

3.3.2&nbsp;&nbsp;&nbsp; By end-use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Key market trends

3.7&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.8&nbsp;&nbsp;&nbsp; Technology landscape

3.9&nbsp;&nbsp;&nbsp; Future market trends

3.10&nbsp;&nbsp;&nbsp; Value chain analysis

3.11&nbsp;&nbsp;&nbsp; Gap Analysis

3.12&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.13&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Vendor matrix analysis

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Liver Cancer Diagnostics Market Size and Forecast, By Test Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by test type

5.2&nbsp;&nbsp;&nbsp; Laboratory test

5.2.1&nbsp;&nbsp;&nbsp; Biomarkers

5.2.2&nbsp;&nbsp;&nbsp; Blood Tests

5.3&nbsp;&nbsp;&nbsp; Imaging test

5.4&nbsp;&nbsp;&nbsp; Biopsy

5.5&nbsp;&nbsp;&nbsp; Endoscopy

5.6&nbsp;&nbsp;&nbsp; Genomic test

5.7&nbsp;&nbsp;&nbsp; Others

Chapter 6&nbsp;&nbsp;&nbsp;Liver Cancer Diagnostics Market Size and Forecast, By End-use (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

6.2&nbsp;&nbsp;&nbsp; Hospitals

6.3&nbsp;&nbsp;&nbsp; Diagnostic laboratories

6.4&nbsp;&nbsp;&nbsp; Academic and research institutes

6.5&nbsp;&nbsp;&nbsp; Others

Chapter 7&nbsp;&nbsp;&nbsp;Liver Cancer Diagnostics Market Size and Forecast, By Region (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by region

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; France

7.3.4&nbsp;&nbsp;&nbsp; Spain

7.3.5&nbsp;&nbsp;&nbsp; Italy

7.3.6&nbsp;&nbsp;&nbsp; Sweden

7.3.7&nbsp;&nbsp;&nbsp; Poland

7.3.8&nbsp;&nbsp;&nbsp; The Netherlands

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; China

7.4.2&nbsp;&nbsp;&nbsp; Japan

7.4.3&nbsp;&nbsp;&nbsp; India

7.4.4&nbsp;&nbsp;&nbsp; Australia

7.4.5&nbsp;&nbsp;&nbsp; South Korea

7.4.6&nbsp;&nbsp;&nbsp; Indonesia

7.4.7&nbsp;&nbsp;&nbsp; Thailand

7.4.8&nbsp;&nbsp;&nbsp; Philippines

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.5.4&nbsp;&nbsp;&nbsp; Colombia

7.5.5&nbsp;&nbsp;&nbsp; Chile

7.5.6&nbsp;&nbsp;&nbsp; Peru

7.6&nbsp;&nbsp;&nbsp; MEA

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; UAE

7.6.4&nbsp;&nbsp;&nbsp; Israel

7.6.5&nbsp;&nbsp;&nbsp; Egypt

7.6.6&nbsp;&nbsp;&nbsp; Turkey

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; AB SCIEX

8.2&nbsp;&nbsp;&nbsp; Agilent Technologies Inc.

8.3&nbsp;&nbsp;&nbsp; Becton, Dickinson &amp; Company

8.4&nbsp;&nbsp;&nbsp; Biocare Medical, LLC

8.5&nbsp;&nbsp;&nbsp; bioM&eacute;rieux SA

8.6&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories, Inc.

8.7&nbsp;&nbsp;&nbsp; Danaher Corporation

8.8&nbsp;&nbsp;&nbsp; Epigenomics Ag

8.9&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

8.10&nbsp;&nbsp;&nbsp; General Electric Company

8.11&nbsp;&nbsp;&nbsp; Hoffmann La-Roche Ltd.

8.12&nbsp;&nbsp;&nbsp; Hologic, Inc.

8.13&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

8.14&nbsp;&nbsp;&nbsp; Koninklijke Philips N.V.

8.15&nbsp;&nbsp;&nbsp; Qiagen N.V.

8.16&nbsp;&nbsp;&nbsp; Seimens Healthineers

8.17&nbsp;&nbsp;&nbsp; Sysmex Corporation

&nbsp;

Liver Cancer Diagnostics Market

Get a free sample of this report